Windward Bio director Bonita reports OrbiMed holdings
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Windward Bio Group AG (WWB) director David P. Bonita disclosed positions held of record by OrbiMed Private Investments IX, LP: 3,561,936 and 1,611,008 Common Shares underlying Series A and Series B Preferred Shares, respectively; 216,668 underlying warrants; and 531,632 Common Shares. The preferred shares convert one-for-one immediately before the issuer’s IPO. Warrants are exercisable at $0.02 and expire May 12, 2036. Bonita, an OrbiMed Advisors member, disclaims beneficial ownership except to the extent of any pecuniary interest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Series A Preferred Shares F3, F1, F2 | -- | -- | -- |
| Holding | Series B Preferred Shares F3, F1, F2 | -- | -- | -- |
| Holding | Warrants (right to buy) F5, F4, F1, F2 | -- | -- | -- |
| Holding | Common Shares F1, F2 | -- | -- | -- |
Footnotes (5)
- F1. These securities are held of record by OrbiMed Private Investments IX, LP. ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. The Reporting Person is a member of OrbiMed Advisors.
- F2. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
- F3. Each Series A Preferred Share and Series B Preferred Share will automatically convert into the number of Common Shares on a 1-to-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
- F4. The warrants are fully vested and exercisable.
- F5. The exercise price is in US Dollars and reflects the conversion of CHF to USD at an exchange rate of $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the Issuer's board of directors.
Key Figures
Key Terms
initial public offering financial
voting and investment power regulatory
beneficial ownership regulatory
fully vested and exercisable technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What WWB securities are listed for director David P. Bonita?
What are the exercise price and expiration date of the WWB warrants?
Who holds the WWB securities, and what is David P. Bonita’s connection?
AI-generated analysis. How Rhea-AI works. Not financial advice.